Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

430 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targeted Radiolabeled Compounds in Glioma Therapy.
Cordier D, Krolicki L, Morgenstern A, Merlo A. Cordier D, et al. Among authors: merlo a. Semin Nucl Med. 2016 May;46(3):243-9. doi: 10.1053/j.semnuclmed.2016.01.009. Semin Nucl Med. 2016. PMID: 27067505 Review.
Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with 213Bi-substance P analogue.
Krolicki L, Bruchertseifer F, Kunikowska J, Koziara H, Królicki B, Jakuciński M, Pawlak D, Apostolidis C, Mirzadeh S, Rola R, Merlo A, Morgenstern A. Krolicki L, et al. Among authors: merlo a. Eur J Nucl Med Mol Imaging. 2018 Jul;45(9):1636-1644. doi: 10.1007/s00259-018-4015-2. Epub 2018 Apr 30. Eur J Nucl Med Mol Imaging. 2018. PMID: 29713762 Free PMC article.
225Ac- and 213Bi-Substance P Analogues for Glioma Therapy.
Królicki L, Kunikowska J, Bruchertseifer F, Koziara H, Królicki B, Jakuciński M, Pawlak D, Rola R, Morgenstern A, Rosiak E, Merlo A. Królicki L, et al. Among authors: merlo a. Semin Nucl Med. 2020 Mar;50(2):141-151. doi: 10.1053/j.semnuclmed.2019.11.004. Semin Nucl Med. 2020. PMID: 32172799 Free article. Review.
Dose escalation study of targeted alpha therapy with [225Ac]Ac-DOTA-substance P in recurrence glioblastoma - safety and efficacy.
Królicki L, Bruchertseifer F, Kunikowska J, Koziara H, Pawlak D, Kuliński R, Rola R, Merlo A, Morgenstern A. Królicki L, et al. Among authors: merlo a. Eur J Nucl Med Mol Imaging. 2021 Oct;48(11):3595-3605. doi: 10.1007/s00259-021-05350-y. Epub 2021 Apr 15. Eur J Nucl Med Mol Imaging. 2021. PMID: 33860346 Free PMC article. Clinical Trial.
Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial.
Cordier D, Forrer F, Bruchertseifer F, Morgenstern A, Apostolidis C, Good S, Müller-Brand J, Mäcke H, Reubi JC, Merlo A. Cordier D, et al. Among authors: merlo a. Eur J Nucl Med Mol Imaging. 2010 Jul;37(7):1335-44. doi: 10.1007/s00259-010-1385-5. Epub 2010 Feb 16. Eur J Nucl Med Mol Imaging. 2010. PMID: 20157707 Free article. Clinical Trial.
Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance p.
Kneifel S, Cordier D, Good S, Ionescu MC, Ghaffari A, Hofer S, Kretzschmar M, Tolnay M, Apostolidis C, Waser B, Arnold M, Mueller-Brand J, Maecke HR, Reubi JC, Merlo A. Kneifel S, et al. Among authors: merlo a. Clin Cancer Res. 2006 Jun 15;12(12):3843-50. doi: 10.1158/1078-0432.CCR-05-2820. Clin Cancer Res. 2006. PMID: 16778112
430 results